The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 337)
Improved Biomarkers & Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD
LRRK2 Biology Consortium, 2017
To avoid accumulation of products that may cause toxicity, neurons rely on a series of highly efficient mechanisms of quality control. It has been proposed that, in those with Parkinson's disease (PD), some of these mechanisms may not function properly, leading to increased cellular toxicity and contributing to cellular malfunctions in the brain. However, assessing the magnitude ...
Researchers: Fernando Macian, PhD/MD
Target Validation Award, 2017
Mitochondria provide energy for neurons to function and survive. Evidence suggests that individuals with Parkinson's disease (PD) have poorly functioning mitochondria, such that the energy demand is not met and toxic products build up and cause damage to neurons. USP30 is a newly discovered protein that regulates the clearance of poorly functioning mitochondria by modifying levels...
Researchers: Paul Thompson, PhD
Improved Biomarkers and Clinical Outcome Measures, 2017
Using Automatic Acoustic Speech Analysis and REM Sleep Behavior Disorder to Detect Individuals at High Risk of Parkinson's Disease and Other Alpha-synucleinopathies
Speech is an important indicator of motor function and movement coordination and can be extremely sensitive to the progression of neurologic diseases. The aim of this project is to use simple speech recording and high-end pattern analysis to detect pre-clinical stages of disabling central nervous system disorders including Parkinson's disease (PD) and other alpha-synucleinopathies...
Researchers: Jan Rusz, PhD
Oligomeric & pS129 Assay Leaps 2016, 2017
The alpha-synuclein protein is a key player in Parkinson's disease (PD). Our ability to understand how this protein impacts the health of neurons in the brain is directly related to the tools we have at hand to study it. This study aims to validate an assay (test) designed to measure the amount of specifically modified versions of the protein in cerebrospinal fluid (baths the brai...
Researchers: Deniz Kirik, MD, PhD